"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2009 | 3 | 1 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 2 | 3 | 5 |
| 2013 | 2 | 2 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 6 | 1 | 7 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 2 | 5 |
| 2019 | 6 | 0 | 6 |
| 2020 | 3 | 3 | 6 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 3 | 3 |
| 2025 | 3 | 0 | 3 |
| 2026 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Netw Open. 2026 Jun 01; 9(6):e2618581.
-
Impact of Disease-Specific Treatment and Non-Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC. Liver Int. 2026 05; 46(5):e70628.
-
Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study. BMJ Open Gastroenterol. 2026 Mar 27; 13(1).
-
SARS-CoV-2 infectious shedding and rebound among adults with and without oral antiviral use: two case-ascertained prospective household studies. Lancet Microbe. 2026 Jan; 7(1):101227.
-
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non-Hodgkin Lymphoma in Patients with Chronic Hepatitis C. Cancer Epidemiol Biomarkers Prev. 2025 Nov 03; 34(11):2025-2031.
-
Care at home for remdesivir treatment of COVID-19: a survey study of patient and physician experiences. BMC Infect Dis. 2025 Oct 23; 25(1):1398.
-
Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. Pediatrics. 2025 Aug 01; 156(2).
-
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern Med. 2024 Sep 01; 184(9):1024-1034.
-
Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system. Sci Rep. 2024 03 29; 14(1):7485.
-
Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Feb; 41(2):744-758.